Study of NSI-189 for Major Depressive Disorder

PHASE2UnknownINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

December 31, 2017

Conditions
Major Depressive Disorder
Interventions
DRUG

80 Milligrams NSI-189

Orally Administered

DRUG

Placebo

Orally administered

DRUG

40 Milligrams NSI-189

Orally Administered

Trial Locations (13)

10312

Richmond Behavioral Associates, Staten Island

30005

Institute for Advanced Medical Research, Alpharetta

32256

Clinical Neuroscience Solutions, Inc., Jacksonville

32801

Clinical Neuroscience Solutions, Inc, Orlando

38119

Clinical Neuroscience Solutions, Inc., Memphis

45417

Midwest Clinical Research Center, LLC, Dayton

60076

Psychiatric Medicine Associates, LLC, Skokie

63141

St. Louis Clinical Trials, LC, St Louis

75231

FutureSearch Trials of Dallas, Dallas

78229

Clinical Trials of Texas, Inc., San Antonio

80209

Clinical Trials of the Rockies, Denver

91950

Synergy San Diego, National City

92845

Collaborative Neuroscience Network, LLC, Garden Grove

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Neuralstem Inc.

INDUSTRY